Clinical Trial Update: FimasaRtan-basEd BP Targets After Drug SwitcHing

View source ↗

Summary

A completed clinical trial evaluating a fimasartan-based blood pressure target after drug switching for essential hypertension; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• FimasaRtan-based (fimasaRtan-based agent)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Essential Hypertension | Status: COMPLETED | Results posted: 2020-12-21